- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05556681
Study of BD Sirolimus Drug Coated Catheter for Treatment of Femoropopliteal Arteries (PREVISION)
January 29, 2024 updated by: C. R. Bard
Prospective, Multicenter, Single Arm, Non-Randomized Study of BD Sirolimus Drug Coated Catheter for Treatment of Femoropopliteal Arteries
The objective of this early feasibility study is to assess the safety and performance of the BD™ Sirolimus Drug Coated Balloon Catheter.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
This is a prospective, multi-center, non-randomized, single-arm early feasibility study designed to assess the safety and performance of the BD™ Sirolimus Drug Coated Balloon Catheter for the treatment of stenosis in the femoropopliteal arteries.
Follow-up for all treated subjects will be performed at post-procedure, 30 days, and 6, 12 months, 18 months and 24 months post-index procedure.
Study Type
Observational
Enrollment (Actual)
34
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Josh Smale
- Phone Number: +16028305078
- Email: josh.smale@bd.com
Study Contact Backup
- Name: Ryan Melloy
- Phone Number: +16028305481
- Email: ryan.melloy@bd.com
Study Locations
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Royal Prince Alfred Hospital
-
St Leonards, New South Wales, Australia, 2065
- Royal North Shore Hospital
-
-
Queensland
-
Southport, Queensland, Australia, 4215
- Gold Coast University Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5001
- Flinders University
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- The Alfred
-
-
Western Australia
-
Perth, Western Australia, Australia, 6000
- Royal Perth Hospital
-
-
-
-
Auckland
-
Grafton, Auckland, New Zealand, 1023
- Auckland City Hospital
-
-
Waikato
-
Hamilton, Waikato, New Zealand, 3204
- Waikato Hospital
-
-
-
-
-
Novena, Singapore, 308433
- Tan Tock Seng Hospital
-
Punggol, Singapore, 544886
- Sengkang General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 89 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The intended population for this study is those who suffer from obstructive vascular lesions in the femoropopliteal arteries with the purpose of improving limb perfusion and decreasing the incidence of restenosis.
The intended population must meet all study criteria to be included in this clinical research study.
Description
Inclusion Criteria:
Pre-Operative Inclusion Criteria:
- ≥18 years of age
- Rutherford Clinical Category 2-4
- Patient is willing to provide informed consent, is geographically stable, comply with the required follow up visits, testing schedule, and recommended medication regimen
- Women of childbearing potential who have a negative urine pregnancy test (UPT) at screening
Angiographical Inclusion Criteria:
- One Lesion of ≥ 3 cm and ≤ 17 cm in length (if two discrete lesions are separated by ≤ 3 cm, but both falling within a composite length of ≤ 17 cm, they may be treated as one lesion).
- Lesion ≥70% stenosis by visual estimate
- Lesion location starts ≥1 cm below the common femoral bifurcation and terminates distally ≥2 cm above the tibial plateau.
- De novo or non-stented restenotic lesion(s) in native femoropopliteal arteries >90 days from prior interventional procedure
- Lesion is located at least 3 cm from any stent
- Target reference vessel diameter of 5-6 mm and able to be treated with available device size matrix
- Successful, uncomplicated (without use of crossing device, specialty 035 guidewire are acceptable) antegrade wire crossing of lesion
- Successful vessel preparation of the target lesion. Successful vessel preparation is defined by successful pre-dilatation to nominal of the target lesion, in the absence of early recoil, significant residual stenosis ≤30% as confirmed by angiography without any major vascular complications or flow-limiting dissections.
- A patent inflow artery free from significant lesion stenosis (≥50% stenosis) as confirmed by standard of care imaging and the discretion of the investigator. Only treatment of ipsilateral iliac inflow arteries is acceptable before the treatment of the target lesion, defined as attainment of residual diameter stenosis ≤30% without death or major vascular complication
- At least one patent native outflow artery to the ankle, free from significant (≥50%) stenosis as confirmed by angiography, that has not previously been revascularized (outflow to be assessed after successful vessel preparation of target lesion; treatment of outflow disease is NOT permitted during the index procedure)
Exclusion Criteria:
Pre-Operative Exclusion Criteria:
- ≥ 90 years of age
- Women who are breastfeeding, currently pregnant or planning to become pregnant during the duration of the study or have a positive urine pregnancy test at screening. Men who are intending to biologically father children during the duration of the study
- Life expectancy of <2 years
- Participant has acute limb ischemia
- Previous treatment of the target limb using Drug Coated Balloon (DCB), a stent, or Drug Eluting Stent (DES) within the last 180 days.
- Previous treatment of the contralateral limb using Drug Coated Balloon (DCB) or Drug Eluting Stent (DES) within the last 90 days.
- History of stroke or Transient Ischemic Attack (TIA) within 90 days.
- History of myocardial infarction (MI), thrombolysis or angina within 30 days of index procedure
- Renal failure (on dialysis) or chronic kidney disease (Glomerular Filtration Rate (GFR) < 30 ml/min per 1.73m2 (or serum creatinine ≥2.5 mg/L within 30 days of index procedure or treated with dialysis)) that in the opinion of the investigator should preclude participant enrollment in the study
- Active or suspected active infection at time of index procedure that in the opinion of the investigator should preclude participant enrollment in the study
- Patients with any type of previous or planned surgical or interventional procedure within 30 days prior and/or within 30 days post-index procedure
- Sudden symptom onset (within two weeks), acute vessel occlusion, or acute or sub-acute thrombus in target vessel or history of treatment of thrombolysis in the target legion
- Known contraindication (including allergic reaction) or sensitivity to sirolimus (rapamycin).
- Known contraindication (including reaction) or sensitivity to iodinated contrast media, that cannot be adequately managed with pre- and post-procedure medication. CO2 angiography is not allowed.
- Has received systemic immunosuppressants or immunemodifying drugs for >14 days in total within 3 months prior to Screening (for corticosteroids ≥ 20 mg/day of prednisone equivalent, excluding standard of care use of inhaled corticosteroids).
- Immunosuppressive or immunodeficient state, in the opinion of the investigator, that would preclude the participant from being eligible to be treated with a sirolimus DCB. Note: HIV positive participants with CD4 count ≥350 cells/mm3 and an undetectable HIV viral load within the past year [low level variations from 50-500 viral copies which do not lead to changes in antiretroviral therapy [ART] are permitted.
- Has active malignancy prior to study entry
- Bleeding diathesis, Gastrointestinal ulceration, another coagulopathy disorder, or allergy in the opinion of the investigator, which would restrict the use of anticoagulant or dual antiplatelet therapy (DAPT)
- Participant is currently participating in an investigational drug or device study, or previously enrolled in a trial within the last 30 days prior to screening. Enrollment in another investigational drug or device study during the follow up period for this study is not allowed.
- Current alcohol or drug abuse that in the opinion of the investigator should preclude participant enrollment in the study
- Participant has a condition that in the opinion of the investigator should preclude participant enrollment in the study
Angiographical Exclusion Criteria:
- Severe Calcification as defined as PARC scoring system (> 180 degrees (both sides of the vessel at the same location) and greater than one-half of the total lesion length) of the target lesion.
- Intended use of adjunctive primary treatment modalities (e.g., atherectomy, laser, cutting balloons, radiation therapy, stents, other drug coated devices.)
- Use of reentry devices during the index procedure for antegrade recanalization, which include but are not limited to percutaneous intentional extraluminal recanalization (PIER) and subintimal arterial flossing with antegrade retrograde intervention (SAFARI) techniques.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Treated with the investigational BD™ Sirolimus Drug Coated Catheter
Patients treated with the BD™ Sirolimus Drug Coated Catheter
|
The study will enroll patients presenting with clinical evidence of an angiographically significant lesion (Lesion ≥ 70% stenosis by visual estimate) in the femoropopliteal arteries.
After pre-dilatation, patients will undergo angioplasty with the investigational BD™ Sirolimus Drug Coated Balloon Catheter.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Late lumen loss at six months as measured by quantitative vascular angiography (QVA).
Time Frame: at 6 month follow-up
|
Late lumen loss is defined as the difference (in mm) between the minimum lumen diameter (MLD) of the treated segment at follow up and the measurement immediately after the index procedure.
|
at 6 month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rutherford Improvement
Time Frame: at discharge, and 1, 6, 12 and 24 month follow-up
|
This endpoint will be evaluated by descriptive statistics and will not have statistical analyses associated with them but will be reported upon in the final study report.
|
at discharge, and 1, 6, 12 and 24 month follow-up
|
Patient Reported Outcome Improvement
Time Frame: at post-procedure, and 1, 6, 12 and 24 month follow-up
|
This endpoint will be evaluated by descriptive statistics and will not have statistical analyses associated with them but will be reported upon in the final study report.
|
at post-procedure, and 1, 6, 12 and 24 month follow-up
|
Freedom of Embolization
Time Frame: at discharge, and 1, 6, 12 and 24 month follow-up
|
This endpoint will be evaluated by descriptive statistics and will not have statistical analyses associated with them but will be reported upon in the final study report.
|
at discharge, and 1, 6, 12 and 24 month follow-up
|
ABI Improvement
Time Frame: at discharge, and 1, 6, 12 and 24 month follow-up
|
This endpoint will be evaluated by descriptive statistics and will not have statistical analyses associated with them but will be reported upon in the final study report.
|
at discharge, and 1, 6, 12 and 24 month follow-up
|
Revascularization rate (CD-TLR)
Time Frame: at discharge, and 1, 6, 12 and 24 month follow-up
|
This endpoint will be evaluated by descriptive statistics and will not have statistical analyses associated with them but will be reported upon in the final study report.
|
at discharge, and 1, 6, 12 and 24 month follow-up
|
Technical & Procedural Success statistical analyses associated with them but will be reported upon in the final study report.
Time Frame: at discharge, and 1, 6, 12 and 24 month follow-up
|
This endpoint will be evaluated by descriptive statistics and will not have statistical analyses associated with them but will be reported upon in the final study report.
|
at discharge, and 1, 6, 12 and 24 month follow-up
|
All Cause Death statistical analyses associated with them but will be reported upon in the final study report.
Time Frame: at discharge, and 1, 6, 12 and 24 month follow-up
|
This endpoint will be evaluated by descriptive statistics and will not have statistical analyses associated with them but will be reported upon in the final study report.
|
at discharge, and 1, 6, 12 and 24 month follow-up
|
Major Adverse Cardiovascular Events (MACE) statistical analyses associated with them but will be reported upon in the final study report.
Time Frame: at discharge, and 1, 6, 12 and 24 month follow-up
|
This endpoint will be evaluated by descriptive statistics and will not have statistical analyses associated with them but will be reported upon in the final study report.
|
at discharge, and 1, 6, 12 and 24 month follow-up
|
Safety Composite statistical analyses associated with them but will be reported upon in the final study report.
Time Frame: at discharge, and 1, 6, 12 and 24 month follow-up
|
This endpoint will be evaluated by descriptive statistics and will not have statistical analyses associated with them but will be reported upon in the final study report.
|
at discharge, and 1, 6, 12 and 24 month follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 2, 2022
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
September 12, 2022
First Submitted That Met QC Criteria
September 22, 2022
First Posted (Actual)
September 27, 2022
Study Record Updates
Last Update Posted (Actual)
January 30, 2024
Last Update Submitted That Met QC Criteria
January 29, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Atherosclerosis
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- BDPI-20-012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Data in aggregate
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on BD™ Sirolimus Drug Coated Balloon Catheter angioplasty
-
Spectranetics CorporationCompletedPeripheral Arterial DiseaseBelgium, Germany, France, United Kingdom, Austria, Italy
-
Konkuk University Medical CenterUnknownVascular Graft Anastomotic Stenosis
-
Spectranetics CorporationCompleted
-
Cantonal Hospital of St. GallenUnknownRenal InsufficiencySwitzerland
-
The First Affiliated Hospital of Zhengzhou UniversityUnknownVertebral Artery StenosisChina
-
C. R. BardCompletedArteriosclerosis | Atherosclerosis | Vascular DiseaseGermany, Belgium
-
Medtronic EndovascularCompletedPeripheral Arterial Disease (PAD)Germany
-
B. Braun Melsungen AGErnst von Bergmann HospitalCompletedCoronary Artery Disease (CAD)Germany
-
C. R. BardTerminatedUse and Safety of the LUTONIX® Drug Coated Balloon Catheter in Arteries of the Lower Extremity (LEG)Peripheral Artery DiseaseMalaysia, New Zealand, Canada
-
King Abdullah International Medical Research CenterTerminatedDysfunctional Dialysis Arteriovenous FistulaSaudi Arabia